Soley Bayraktar, MD
Hematology · Safety Harbor, FLNPI 1437331493
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.3% of the total across 49 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 16.4% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for hematology clinicians in FL, where the typical reported total is $1,704.
Across 49 payments — averaging $21.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$170
- Novartis$141
- E.r. Squibb & Sons, L.L.C.$140
- Pharmacyclics LLC, An Abbvie Company$83
- Rigel Pharmaceuticals, Inc.$53
- Bristol Myers Squibb$48
- plus $401 from 18 others
What the payments were for
- Speaking & faculty fees$909%
- Food & beverage$94691%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 5 | $170 |
| Novartis | 6 | $141 |
| E.r. Squibb & Sons, L.L.C. | 9 | $140 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $83 |
| Rigel Pharmaceuticals, Inc. | 3 | $53 |
| Bristol Myers Squibb | 3 | $48 |
| Daiichi Sankyo Inc. | 2 | $46 |
| Pfizer | 2 | $38 |
| Beigene USA, Inc. | 2 | $32 |
| Amgen | 2 | $29 |
| Regeneron Healthcare Solutions, Inc. | 1 | $23 |
| Astellas Pharma US Inc | 1 | $22 |
| GSK | 1 | $21 |
| Servier Pharmaceuticals LLC | 1 | $21 |
| Jazz Pharmaceuticals Inc. | 1 | $20 |
| Array Biopharma Inc | 1 | $20 |
| Merck | 1 | $19 |
| Gilead | 1 | $18 |
| Mirati Therapeutics, Inc. | 1 | $17 |
| AstraZeneca | 1 | $16 |
| Incyte Corporation | 1 | $15 |
| Lilly USA, LLC | 1 | $14 |
| Seagen Inc. | 1 | $13 |
| Johnson & Johnson | 1 | $13 |
How this compares
$1,036 in reported general payments places this provider in the 45th percentile of 79 hematology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 52 | $510,900 |
| KisqaliRibociclib Succinate | 19 | $308,130 |
| IbrancePalbociclib | 17 | $266,543 |
| ImbruvicaIbrutinib | 16 | $249,262 |
| VenclextaVenetoclax | 14 | $230,708 |
| BosulifBosutinib | 14 | $178,977 |
| BrukinsaZanubrutinib | 11 | $169,617 |
| EliquisApixaban | 52 | $42,540 |
| XareltoRivaroxaban | 39 | $42,212 |
| Ondansetron Hcl | 67 | $3,299 |
| Anastrozole | 104 | $1,903 |
| Letrozole | 113 | $1,744 |
| Acyclovir | 65 | $1,215 |
| Hydroxyurea | 66 | $920 |
| Prochlorperazine Maleate | 81 | $908 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance, Bosulif, Eliquis | $38 | $488,06083 claims |
| NovartisKisqali | $141 | $308,13019 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $83 | $249,26216 claims |
| Beigene USA, Inc.Brukinsa | $32 | $169,61711 claims |
| Johnson & JohnsonXarelto | $13 | $42,21239 claims |
| Lilly USA, LLCOlanzapine | $14 | $10833 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 79 hematology providers in Florida.
Other hematology in Safety Harbor
- Javier Pinilla-IbarzTampa$1.6M
- Rami KomrokjiTampa$855K
- Ahmed ZakariAltamonte Springs$383K
- Alex Mejia GarciaVero Beach$302K
- Doris HansenTampa$141K
- Juan VarelaOrlando$131K
- Firas El ChaerMiami$105K
- Philip PancariOrlando$70K
- Melissa AlsinaTampa$64K
- Terrence BradleyMiami$53K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.